Format

Send to

Choose Destination
Nucl Med Commun. 2015 Sep;36(9):914-21. doi: 10.1097/MNM.0000000000000339.

Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.

Author information

1
aPET/CT of Imaging Department, Sichuan Cancer Hospital bNational Engineering Research Center for Biomaterials cDepartment of Radiology, West China Hospital, Sichuan University, Chengdu dThe Third People's Hospital of Chengdu, Chengdu eWuxi Molecular Imaging CRO Co. Ltd, Wuxi, People's Republic of China.

Abstract

OBJECTIVE:

(18)F-Fluorodeoxyglucose ((18)F-FDG), (18)F-fluoro-3'-deoxy-3'-L-fluorothymidine ((18)F-FLT), (18)F-fluoromisonidazole ((18)F-FMISO), and (18)F-AlF-NOTA-PRGD2 ((18)F-RGD) are all commonly used PET tracers for tumor diagnosis based on different mechanisms of tissue uptake. This study compared the ex-vivo biodistribution and PET/computed tomography (CT) imaging studies of these four PET tracers in a xenograft prostate tumor-bearing mouse model.

MATERIALS AND METHODS:

Nude mice were inoculated with 5 × 10 PC-3 cells in the right armpit. The ex-vivo biodistribution of (18)F-FDG, (18)F-FLT, (18)F-FMISO, and (18)F-RGD at 30, 60, 90, and 120 min after injection was compared. Micro-PET/CT images of (18)F-FDG, (18)F-FLT, and (18)F-RGD were acquired at 60 min, whereas (18)F-FMISO images were acquired at 90 min after injection.

RESULTS:

The tumors were clearly visualized by micro-PET/CT using all four PET tracers. Ex-vivo biodistribution results showed highest tumor accumulation and tumor-to-muscle ratio of (18)F-FDG at each time point, accompanied by physiologically high uptakes in the brain, heart, and intestinal tract. Modest uptake of (18)F-FLT and (18)F-FMISO in tumors was observed at 60 and 90 min after injection, with less interference from other tissues compared with (18)F-FDG. Besides, (18)F-RGD also exhibited high tumor specificity; however, relatively low uptake was observed in the tumor.

CONCLUSION:

Our results demonstrated the potential of (18)F-FMISO and (18)F-FLT in the diagnosis of xenograft prostate cancer.

PMID:
25973694
DOI:
10.1097/MNM.0000000000000339
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center